Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079631 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 482
- Enrollment target
- 13
- Study locations
NCT07079631: Recruiting Phase 1 study of Metastatic Colorectal Cancer, sponsored by BioNTech SE.
NCT07079631 is a Phase 1 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 482 participants, above the 175-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (175% higher). The trial reports 13 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07079631, a Phase 1 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 482 participants
- Enrollment target
- 13
- Study locations
Study Summary
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC). This study will enroll participants with microsatellite stable or mismatch repair proficient (MSS/pMMR) mCRC who did not respond well to their first schema of chemotherapy. In one part of the study (i.e., Part B) mCRC participants will be enrolled, who have not received any systemic therapy before for their cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG BNT327
- BIOLOGICAL BNT314
- DRUG SoC chemotherapy treatment 1
- DRUG SoC chemotherapy treatment 2
Study Locations (13)
Other
- Hämatologisch-Onkologische Praxis Eppendorf - HOPE - Hamburg
- Asklepios Tumorzentrum Hamburg - Hamburg
- National Cancer Center Hospital East - Kashiwa
- Hospital HM Nou Delfos - Barcelona
- Vall D'Hebrón Hospital - Barcelona
- Centro Integral Oncologico Clara Campal - Madrid
- Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital - London
- Christie NHS Foundation - Manchester
- The Royal Marsden NHS - Sutton
Connecticut
- Yale University - New Haven
Michigan
- START Midwest - Grand Rapids
Ohio
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center - Cleveland
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2031-05 |
| Phase | Phase 1 |
What NCT07079631 shows while recruiting
NCT07079631 is an interventional study that assigns participants to a tested intervention. The registered 482 participants enrollment target is mid-sized for trials with a published cap, above the 175-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (175% higher).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07079631 lists 13 locations in 5 states (Other, Connecticut, Michigan).
Frequently Asked Questions
What is clinical trial NCT07079631 about?
NCT07079631 is a clinical study titled "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer". This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorect...
What is the current status of trial NCT07079631?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 482 participants. The study started on 2025-07-18. Estimated completion is 2031-05.
What conditions does trial NCT07079631 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT07079631?
The interventions under investigation include: Bevacizumab (DRUG), BNT327 (DRUG), BNT314 (BIOLOGICAL), SoC chemotherapy treatment 1 (DRUG), SoC chemotherapy treatment 2 (DRUG).
Who is sponsoring clinical trial NCT07079631?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07079631 being conducted?
This trial has 13 study locations across Connecticut, Michigan, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07079631's enrollment target sits among peer trials
482 4th of 45 higher than 42 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI